Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2025-03-18 Director's Dealing
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report changes in shareholdings by insiders or major shareholders, which corresponds to the 'Director's Dealing' (DIRS) category in the provided taxonomy.
2025-03-18 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company '비보존 제약'. It outlines the date, location, and agenda items (such as financial statement approval and director compensation) for the upcoming meeting. This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-03-13 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted by 'Vivozon Pharmaceutical' regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for choosing this date and acknowledges the company's non-participation in the voluntary shareholder meeting dispersion program. Since this is a regulatory notification regarding meeting logistics rather than the meeting materials themselves or the results, it falls under the general regulatory filing category.
2025-03-13 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Vivozon Pharmaceutical. It contains the meeting agenda, details on voting procedures, and extensive financial statements (balance sheet, income statement, etc.) as part of the 'Management Reference' (경영참고사항) required for shareholders to review before the meeting. While it contains financial data, it is not a standalone Annual Report (10-K) but rather the official notice and supporting materials for the AGM. Therefore, it is classified as AGM Information.
2025-03-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Vivozon Pharmaceutical) announcing a significant change in financial structure (revenue/profit fluctuation of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to report material financial changes before the final audit report is published. It provides key financial highlights and reasons for the change, fitting the definition of an Earnings Release (ER) as it serves as an initial announcement of financial performance metrics. FY 2024
2025-02-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the change in share ownership by a major shareholder (Vivozon Holdings) in the issuing company (Vivozon Pharmaceutical). This type of filing is specifically categorized as 'Director's Dealing' (DIRS) in the provided schema, as it reports insider/major shareholder transactions.
2025-02-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.